Adial Pharmaceuticals provided a business update and reported financial results for Q2 2025. The FDA meeting for AD04, a drug for Alcohol Use Disorder, was successful. Precision strategies were developed with Cytel, and manufacturing agreements were secured. Adial also regained compliance with Nasdaq rules, filed a patent, and completed a public offering.

Financially, the company had $5.9 million in cash as of June 30, 2025. R&D expenses decreased by 28%, G&A expenses decreased by 10%, and net loss decreased to $2.0 million. Adial remains focused on developing therapies for addiction and related disorders, with AD04 showing promise in clinical trials for AUD treatment in heavy drinking patients.

Adial Pharmaceuticals is a biopharmaceutical company focused on addiction therapies. AD04, the lead drug, targets Alcohol Use Disorder in heavy drinkers. The company is committed to advancing innovative treatments for addiction and related disorders. Forward-looking statements outline plans for regulatory approval, partnerships, and potential therapy for other addictive disorders like opioid use disorder and gambling.

Read more at GlobeNewswire: Adial Pharmaceuticals Reports Second Quarter 2025 Financial